[Guangshengtang: Plans to transfer all technology and rights and interests of Desvenlafaxine Sustained Release Tablets to related party Ruitailai for RMB 12.636 million] On September 11, Guangshengtang (300436.SZ) announced that the company planned to sign a "Technology Transfer Contract" with related party Ruitailai and transfer all the technology and rights and interests of the Desvenlafaxine Sustained Release Tablets project it owns to Ruitailai, a related party, with a transaction amount of RMB 12.636 million. The drug is used to treat severe depression in adults and will help enrich the company's product pipeline and strengthen sales synergy with existing products. Ruitailai's desvenlafaxine succinate extended-release tablets have completed process verification for the 50mg and 25mg specifications and bioequivalence studies for the 50mg specification, and obtained an invention patent for an oral solid preparation and its preparation method. It has not yet submitted a drug registration and marketing application. This transaction constitutes a related transaction and has been reviewed and approved by the board of directors.